Riskpilot← Back to searchSign inGet full accessSista versen 84312 AB
ABDissolvedOrg 5568633381Wholesale of pharmaceutical and medical goods · NACE 4646Est. 20111 employees
Revenue 2023
SEK 499K
+30% vs 2022
EBITDA margin
-13.4%
-322% vs 2022
Equity ratio
2.4%
Financial strength
Net profit 2023
SEK -67K
-321% vs 2022
| Revenue | SEK 499K | +30% |
| EBITDA | SEK -67K | -322% |
| Net profit | SEK -67K | -321% |
| Total assets | SEK 103K | -67% |
| Equity | SEK 2K | -96% |
| Employees | 1 | — |
Legal name
Sista versen 84312 AB
Org number
5568633381
Legal form
Aktiebolag
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
2 september 2011
Share capital
SEK 50 000
Employees
1 (FTE)
VAT registered
No
Audit selected
No
Last report
2023-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamoten suppleanterna
Company purpose
Bolaget ska äga och förvalta fast och lös egendom och därmed förenlig verksamhet.
Address
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Revenue | 809 | 959 | 796 | 384 | 499 |
| Staff expenses | — | — | — | −92 | −0 |
| EBITDA | 228 | 576 | 601 | −16 | −67 |
| Depreciation & amort. | −46 | −30 | −0 | — | — |
| EBIT | 182 | 546 | 601 | −16 | −67 |
| Net financials | — | −1 | — | −0 | 0 |
| Profit before tax | 181 | 545 | 601 | −16 | −67 |
| Tax | −41 | 45 | −0 | — | — |
| Net profit | 140 | 590 | 601 | −16 | −67 |
| Item | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Total assets | 226 | 279 | 835 | 308 | 103 |
| Equity | 51 | 41 | 642 | 69 | 2 |
| Long-term debt | 0 | 0 | 0 | — | — |
| Short-term debt | 175 | 238 | 193 | 239 | 101 |
| Total debt | 175 | 238 | 193 | 239 | 101 |
EBITDA margin
-13.4%
This company
15.8%
Market median
-185% vs market
20192023
Equity ratio
2.4%
This company
38.2%
Market median
-94% vs market
20192023
Return on equity
-2756.0%
This company
18.4%
Market median
-15078% vs market
20192023
Net profit margin
-13.4%
This company
8.1%
Market median
-265% vs market
20192023
Asset turnover
4.84×
This company
1.12×
Market median
+332% vs market
20192023
Debt / equity
41.53×
This company
0.62×
Market median
-6598% vs market
20192023
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
| Name | Role | Member since |
|---|---|---|
| Former (1) | ||
NA Chief Executive Officer | Chief Executive Officer | 2022 – 2024 |
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Deputy Board Member | 2024 | |
| Deputy Board Member | 2024 | |
| Board of Directors | 2024 | |
| Former (2) | ||
| Deputy Board Member | 2022 – 2024 | |
| Deputy Board Member | 2024 – 2024 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Sista versen 84312 AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Nabil Adnan Takwa | Chief Executive Officer | 0 companies |
| Ghaith Takwa | Deputy Board Member | 0 companies |
| Nils Henrik Kristoffer Svensson | Deputy Board Member | 0 companies |
| Lina Anna Elisabeth Nordström | Deputy Board Member | 0 companies |
| Karl-Johan Staffan Tångby | Board of Directors | 0 companies |
| Mohamad Said Takwa | Deputy Board Member | 0 companies |